We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




IVD Cancer Diagnostic Products to be Based on Microarrays

By HospiMedica staff writers
Posted on 05 Sep 2007
Microarray-based tests will enable clinicians to provide more efficient and complete methods to diagnose, classify, and manage patients suffering from cancer.

Affymetrix, Inc. More...
(Santa Clara, CA, USA) and Ipsogen have signed a Powered by Affymetrix (PbA) agreement, which gives Ipsogen (Marseilles, France) non-exclusive access to Affymetrix microarray technology to develop and market in vitro diagnostic (IVD) tests, initially for breast cancer, on a worldwide basis. The PbA agreement enables Ipsogen to incorporate Affymetrix arrays into its diagnostic products.

Ipsogen is a molecular diagnostic company focused on the development and commercialization of innovative diagnostic products to guide treatment options in cancers. "Ipsogen's strong expertise in delivering high medical value IVD products in the field of blood cancers will be leveraged together with our new PbA capabilities to expedite the launch of a range of innovative and unique IVD tests for guiding breast cancer therapies,” said Vincent Fert, president and CEO of Ipsogen.

"The microarray-based tools and applications in the Powered by Affymetrix program continue to accelerate the discovery and development of oncology diagnostics products,” said Noel Doheny, senior vice president, Molecular Diagnostics at Affymetrix. "This is the era of personalized medicine and we are pleased that another innovator in the molecular diagnostic field like Ipsogen has adopted our proven technology platform.”


Related Links:
Affymetrix
Ipsogen

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.